Stockscreener 앱 받기
0.8935
21.56%
0.1585
전일 마감가:
$0.735
열려 있는:
$0.8717
하루 거래량:
10,691
Relative Volume:
15.52
시가총액:
$N/A
수익:
-
순이익/손실:
$-10.38M
주가수익비율:
-0.2345
EPS:
-3.81
순현금흐름:
$-12.45M
1주 성능:
+21.56%
1개월 성능:
+21.56%
6개월 성능:
-83.79%
1년 성능:
-96.88%
1일 변동 폭
$0.8717
$0.957
1주일 범위
$0.8717
$0.957
52주 변동 폭
$0.5231
$0.957
Avenue Therapeutics Inc Stock (ATXI) Company Profile
ATXI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.8935 | 0 | 0 | -10.38M | -12.45M | -3.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.43 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.16 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.33 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.79 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.49 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Avenue Therapeutics Inc 주식(ATXI)의 최신 뉴스
Avenue Therapeutics Inc. (ATXI) Stock Price | Live Quotes & Charts | OTO - StocksToTrade
Avenue Therapeutics Leads Six-Month Stock Performance with 267.29% Return - Markets Mojo
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - Stocktwits
Avenue Therapeutics Leads Six-Month Stock Performance with 253.98% Return - Markets Mojo
Avenue Therapeutics Leads Six-Month Stock Performance with 257.7% Return - Markets Mojo
Village Farms International Leads with 276.7% Return in Recent Six Months - Markets Mojo
Avenue Therapeutics Announces 2025 Annual Meeting Date - The Globe and Mail
[8-K] AVENUE THERAPEUTICS, INC. Reports Material Event | ATXI SEC FilingForm 8-K - Stock Titan
Village Farms International Leads with 282% Return in Recent Performance Surge - Markets Mojo
Village Farms International Leads with 275% Return in Recent Performance Surge - Markets Mojo
Axsome Therapeutics stock hits all-time high at 144.19 USD By Investing.com - Investing.com Nigeria
Avenue Therapeutics Leads Six-Month Stock Performance with 333.85% Return - Markets Mojo
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Avenue Therapeutics Reports Improved Financials Amid Challenges - TipRanks
[10-Q] AVENUE THERAPEUTICS, INC. Quarterly Earnings Report | ATXI SEC FilingForm 10-Q - Stock Titan
Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Village Farms International Leads Six-Month Stock Performance with 424.66% Return - Markets Mojo
ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Avenue Therapeutics Sells Baergic Bio to Axsome - TipRanks
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail
Village Farms International Leads with 418.66% Return in Recent Performance - Markets Mojo
Village Farms International Leads with 354.34% Return in Recent Performance - Markets Mojo
Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics - MSN
Axsome Therapeutics Eyes Baergic Bio: Is This the Next Big CNS Breakthrough? - Smartkarma
Axsome Therapeutics Buys Global Rights To AZD7325 To Expand Epilepsy Pipeline - Pulse 2.0
Deutsche Bank Sticks to Its Sell Rating for AstraZeneca (AZN) - The Globe and Mail
Nebius Group NV Leads Six-Month Stock Performance with 359.83% Return - Markets Mojo
Axsome acquires global rights to AstraZeneca’s epilepsy drug candidate By Investing.com - Investing.com Australia
Avenue shares rights to epilepsy drug candidate with Axsome in deal - Investing.com Nigeria
Axsome acquires global rights to AstraZeneca’s epilepsy drug candidate - Investing.com India
Axsome Therapeutics stock hits all-time high at 139.22 USD By Investing.com - Investing.com South Africa
Axsome Therapeutics stock hits all-time high at 139.22 USD - Investing.com India
Avenue Therapeutics (ATXI) Sells Baergic Bio to Axsome Therapeutics - GuruFocus
AZN Secures Deal with Axsome for Epilepsy Drug Development - GuruFocus
Avenue shares rights to epilepsy drug candidate with Axsome in deal By Investing.com - Investing.com South Africa
Axsome Therapeutics IncObtains Exclusive G - 富途牛牛
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy - The Manila Times
OTC Markets Group Welcomes SUN SILVER LTD. to OTCQX - The Manila Times
Axsome Therapeutics, Inc. entered into an agreement to acquire Baergic Bio, Inc. from Avenue Therapeutics, Inc. for $79.3 million. - MarketScreener
Global Pain Management Devices Market Set to Expand Rapidly at a CAGR of ~8% by 2032 Amid Growing Preference for Minimally Invasive Solutions | DelveInsight - Business Upturn
Nebius Group NV Leads Six-Month Stock Performance with 374.29% Return - Markets Mojo
OVID PRE 14A: approvals for Series B conversion and warrants - Stock Titan
Can Dianthus Therapeutics Inc. stock attract ESG capital inflowsPortfolio Value Summary & AI Driven Price Forecasts - fcp.pa.gov.br
Lirum Therapeutics Announces FDA 'Study May Proceed” Letter Enabling Inclusion of LX-101 in the RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor - The Manila Times
Lirum Therapeutics Announces FDA “Study May Proceed” Letter - GlobeNewswire
Head to Head Survey: Avenue Therapeutics (NASDAQ:ATXI) vs. Neoleukin Therapeutics (NASDAQ:NLTX) - Defense World
Avenue Therapeutics Inc (ATXI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.40%
1.10%
자본화:
|
볼륨(24시간):